Financial updates and company news at Myosin Therapeutics

Company updates

Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

Jupiter, FL – Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular...

June 09, 2025

Company updates

Myosin Therapeutics Announces Key Additions to Its Team as It Prepares to Start Multiple Clinical Trials in Q1 2025

Jupiter, FL – [October 2nd, 2024] – Myosin Therapeutics is pleased to announce the addition...

October 02, 2024

Company updates

Myosin Therapeutics’ Patent Portfolio Strengthened with New Issued Statuses in Australia, Japan, Canada, and Korea

Jupiter, FL – [September 12th, 2024] – Myosin Therapeutics is pleased to announce the expansion...

September 12, 2024

Company updates

Myosin Therapeutics Announces Successful Completion of GMP Drug Substance Manufacturing Campaign for MT-125

Jupiter, FL – [August 31st, 2024] – Myosin Therapeutics is pleased to announce that it...

August 31, 2024

Company updates

Today, Myosin Therapeutics Announces FDA Orphan Drug Designation for MT-125 for the Treatment of Malignant Gliomas

Jupiter, FL – [February 21, 2024] – Today, Myosin Therapeutics is pleased to announce that...

February 21, 2024

Company updates

Myosin Therapeutics Transitions MT-110 to GMP Manufacturing After Meeting Milestones in NIH Blueprint Neurotherapeutics Program

Jupiter, FL – [August 1st, 2023] – Myosin Therapeutics is pleased to announce the successful...

August 01, 2023

Company updates

Dr. Courtney Miller Honored with BioFlorida’s 2022 Weaver H. Gaines Entrepreneur of the Year Award

Jupiter, FL – [November 15, 2022] – Myosin Therapeutics is honored to announce that its...

November 15, 2022